InceptionR’s Travere Therapeutics TVTX Stock Holding History

InceptionR’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,487	Closed	-$251K	–	880
2025 Q3	$251K	Buy	+10,487	New	+$197K	0.06%	526

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

InceptionR's TVTX Position: Q4 2025 in Review

InceptionR sold out of Travere Therapeutics (TVTX) in Q4 2025, closing a stake of 10,487 shares — an estimated $251K sold.

InceptionR first reported a position in TVTX in Q3 2025 and held it in 1 quarter. The position peaked at $251K in Q3 2025. 278 funds tracked by Wall St. Rank hold TVTX as of Q4 2025.

InceptionR reported no remaining Travere Therapeutics position as of Q4 2025 after selling out during the quarter.
InceptionR sold 10,487 Travere Therapeutics shares in Q4 2025, an estimated $251K.
InceptionR first reported a position in Travere Therapeutics in Q3 2025 and held it in 1 quarter.
InceptionR's Travere Therapeutics position peaked at $251K in Q3 2025.
278 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2025.

Based on InceptionR's 13F filing for Q4 2025, filed 11 Feb 2026.